A Phase 2 interventional study of idursulfase beta and idursulfase in Mucopolysaccharidosis II, sponsored by Green Cross Corporation. Status unknown. Open to male participants aged 5 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-01-26.
Sponsored by Green Cross Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the efficacy and safety of three doses of GC1111 in patients with Hunter Syndrome. Participants will be randomized to one of three doses of GC1111 or comparator.
This is a randomized, double-blind, active-controlled, dose-ranging study, where patient will receive one of the three doses of GC1111 (0.5 mg/kg, 1.0 mg/kg, and 1.5 mg/kg) or ELAPRASE 0.5 mg/kg. Approximately 20 patients will be administrated each study drug once every week as an iv infusion for 24 weeks. Efficacy of GC1111 will be evaluated in Six-Minute Walk Test (6MWT), urine Glycosaminoglycans(uGAG), liver and spleen volume, percent predicted Forced Vital Capacity(FVC), and cardiac size and function. Also immunogenicity, Pharmacokinetics(PK) and safety will be evaluated.
77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.
This study's planned enrollment of 20 is close to the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.
Browse Mucopolysaccharidosis II studies →Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
Biological: idursulfase beta
1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
Biological: idursulfase beta
1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
Biological: idursulfase beta
0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
Biological: idursulfase
IV, weekly infusion for 24 weeks
Also known as: GC1111
0.5 mg/kg, iv, weekly infusion for 24 weeks
Also known as: Elaprase
Percent change from baseline in urinary GAG(Glycosaminoglycans) at Week 25
Time frame: Baseline to Week 25
Change from baseline in urinary GAG at Week 25
Time frame: Baseline to Week 25
Change from baseline in Six Minute Walk Test at Week 25
Time frame: Baseline to Week 25
Percent change from baseline in Six Minute Walk Test at Week 25
Time frame: Baseline to Week 25
Change from baseline in Liver volume at Week 25
Liver volume measured by MRI
Time frame: Baseline to Week 25
Percent change from baseline in Liver volume at Week 25
Liver volume measured by MRI
Time frame: Baseline to Week 25
Change from baseline in Spleen volume at Week 25
Spleen volume measured by MRI
Time frame: Baseline to Week 25
Percent change from baseline in Spleen volume at Week 25
Spleen volume measured by MRI
Time frame: Baseline to Week 25
Incidence of Adverse Events and Serious Adverse Events
Time frame: Baseline to Week 25
Safety changes from baseline in clinical laboratory tests, physical examination and vital signs
Time frame: Baseline to Week 25
Immunogenicity
anti-drug-antibody
Time frame: Baseline to Week 25
Pharmacokinetic profile - Area under the serum concentration time curve (AUClast)
Time frame: 1 and 17 week
Pharmacokinetic profile - Maximum observed peak plasma concentration (Cmax)
Time frame: 1 and 17 week
Pharmacokinetic profile - Time at which Cmax is observed (Tmax)
Time frame: 1 and 17 week
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2016, a primary completion of Dec 2019 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idursulfase beta